Abstract 20173: Cardiac Microrna-208a is Upregulated and Positively Correlates With Cardiomyocyte Apoptosis in End Stage Dilated Cardiomyopathy
Introduction: Cardiac miR-208a is dysregulated in several cardiac diseases in which it is associated with adverse outcomes. Our group has previously demonstrated that miR-208a promotes cardiomyocyte apoptosis. Given that many cardiac diseases end with dilated cardiomyopathy, we investigated if miR-208a is upregulated in end stage dilated cardiomyopathy (DCM), and if its expression correlates with cardiomyocyte apoptosis.
Methods and Results: Left ventricular samples were collected from nine patients with end stage DCM who underwent cardiac transplant, and 8 normal controls. miR-208a levels were analyzed by real time-PCR, and apoptosis assay done by TUNEL method. miR-208a was 5.8 times higher in left ventricular samples of end stage DCM patients compared to controls, p=0.014. Patients with DCM also had a significantly higher percentage apoptosis compared to controls, p=0.009,(Figure 1A shows representative TUNEL stained images with increased cardiomyocyte apoptosis in DCM). The level of miR-208a showed a significant positive correlation with percentage cardiomyocyte apoptosis rho(0.597), p=0.011.
Conclusion: Taken together, we showed that miR-208a is elevated in end stage DCM and its levels are positively correlated with cardiomyocyte apoptosis. Targeted silencing of miR-208a may thus be beneficial in DCM and other cardiac diseases that end up in DCM.
Author Disclosures: H. Tony: None. K. Yu: None. M. Wenhan: None. X. Zhao: None. Y. Liu: None. Q. Zeng: None.
- © 2015 by American Heart Association, Inc.